FR11C0020I1 - - Google Patents

Info

Publication number
FR11C0020I1
FR11C0020I1 FR11C0020C FR11C0020I1 FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1 FR 11C0020 C FR11C0020 C FR 11C0020C FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR11C0020I1 publication Critical patent/FR11C0020I1/fr
Application granted granted Critical
Publication of FR11C0020I2 publication Critical patent/FR11C0020I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR11C0020C 1996-12-26 2011-06-21 Dérives difluoroprostaglandines et leur application Active FR11C0020I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (2)

Publication Number Publication Date
FR11C0020I1 true FR11C0020I1 (he) 2011-07-29
FR11C0020I2 FR11C0020I2 (fr) 2012-03-16

Family

ID=27301396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0020C Active FR11C0020I2 (fr) 1996-12-26 2011-06-21 Dérives difluoroprostaglandines et leur application

Country Status (16)

Country Link
US (2) US5886035A (he)
EP (1) EP0850926B1 (he)
JP (2) JP3480549B2 (he)
KR (1) KR100526282B1 (he)
CN (1) CN1108289C (he)
AT (1) ATE225770T1 (he)
CA (1) CA2225761C (he)
DE (2) DE69716226T2 (he)
DK (1) DK0850926T3 (he)
ES (1) ES2187719T3 (he)
FR (1) FR11C0020I2 (he)
LU (1) LU91943I2 (he)
NL (1) NL300407I2 (he)
NO (2) NO317060B1 (he)
PT (1) PT850926E (he)
TW (1) TW536534B (he)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
PT1532981E (pt) * 2002-08-23 2007-12-12 Santen Pharmaceutical Co Ltd Colírios estáveis contendo latanoprost como ingrediente activo
KR101253941B1 (ko) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
EP1666043B1 (en) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
EP2247069B1 (en) * 2003-12-08 2013-09-11 Qualcomm Incorporated High data rate interface with improved link synchronization
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
JP5100025B2 (ja) * 2005-03-31 2012-12-19 旭硝子株式会社 プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
EP1864666B1 (en) * 2005-03-31 2012-08-15 Asahi Glass Company, Limited Protective agent for retinal neuronal cell containing prostaglandin f2 alpha derivative as active ingredient
RU2392938C2 (ru) 2005-04-13 2010-06-27 Убе Индастриз, Лтд Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола
WO2007000642A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
WO2007091697A2 (en) * 2006-02-07 2007-08-16 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2338496A4 (en) * 2008-09-04 2014-07-30 Santen Pharmaceutical Co Ltd AGENT FOR PROMOTING HAIR GROWTH CONTAINING A 15,15-DIFLUOROPROSTAGLANDINE F2alpha DERIVATIVE AS ACTIVE INGREDIENT
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2807301C (en) 2010-08-02 2018-11-27 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
ES2687494T3 (es) 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
TW202126308A (zh) 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013118058A1 (en) * 2012-02-07 2013-08-15 Dr.Reddys Laboratories Limited Amine salts of prostaglandin analogs
EP2857002A4 (en) 2012-05-30 2015-12-09 Asahi Glass Co Ltd COMPOSITION FOR CAPILLARY GROWTH
US20150313825A1 (en) 2012-11-21 2015-11-05 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (he) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103804195B (zh) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103819436A (zh) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 (3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (ko) 2015-03-30 2016-10-10 연성정밀화학(주) 타플루프로스트의 제조방법
JP2018536017A (ja) 2015-09-22 2018-12-06 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための化合物及び組成物
CN107226790A (zh) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 他氟前列素的制备方法
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
CN112851510B (zh) * 2021-01-27 2022-07-19 Ａｇｃ株式会社 他氟前列素的纯化方法
CN112832150B (zh) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 一种涵洞通道等立面垂直凿毛装置
CN116120268A (zh) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 一种他氟前列素中间体异构体杂质及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
ATE202557T1 (de) * 1996-11-12 2001-07-15 Alcon Lab Inc 15-fluoro-prostaglandine als augendrucksenkende mittel

Also Published As

Publication number Publication date
NO317060B1 (no) 2004-08-02
NO976085D0 (no) 1997-12-23
ATE225770T1 (de) 2002-10-15
DE69716226T2 (de) 2003-06-05
US5985920A (en) 1999-11-16
DE69716226D1 (de) 2002-11-14
ES2187719T3 (es) 2003-06-16
FR11C0020I2 (fr) 2012-03-16
US5886035A (en) 1999-03-23
JP3994074B2 (ja) 2007-10-17
KR100526282B1 (ko) 2006-05-17
DE122008000050I2 (de) 2011-06-16
NO2009006I1 (no) 2009-03-16
NL300407I2 (nl) 2010-03-01
PT850926E (pt) 2003-02-28
JP2004002462A (ja) 2004-01-08
DE122008000050I1 (de) 2009-01-29
KR19980064718A (ko) 1998-10-07
JP3480549B2 (ja) 2003-12-22
TW536534B (en) 2003-06-11
LU91943I2 (fr) 2012-04-16
DK0850926T3 (da) 2003-02-17
JPH1171344A (ja) 1999-03-16
CA2225761A1 (en) 1998-06-26
EP0850926B1 (en) 2002-10-09
CA2225761C (en) 2009-04-21
NO976085L (no) 1998-06-29
CN1187486A (zh) 1998-07-15
CN1108289C (zh) 2003-05-14
EP0850926A2 (en) 1998-07-01
EP0850926A3 (en) 1999-06-16
NO2009006I2 (no) 2012-03-05
NL300407I1 (nl) 2009-11-02

Similar Documents

Publication Publication Date Title
FR11C0020I1 (he)
AR026660A2 (he)
BRPI9713914B8 (he)
ITMI960702A0 (he)
IN191779B (he)
IN186424B (he)
IN190220B (he)
IN189571B (he)
IN190924B (he)
ITMI960668A0 (he)
IN188086B (he)
BR9603859A (he)
BR7601346U (he)
BR7600721U (he)
ITMI960474V0 (he)
IN186846B (he)
CN3044347S (he)
CN3045530S (he)
CN3047919S (he)
CN3047747S (he)
CN3047597S (he)
CN3047746S (he)
CN3045806S (he)
EP0896385A4 (he)
CN3040367S (he)